Navigation Links
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
Date:6/6/2009

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today new, positive Phase II study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) analog administered subcutaneously once-weekly for the treatment of type 2 diabetes. These data will be presented as part of the American Diabetes Association's (ADA) 69th Annual Scientific Sessions.

In the Phase II study, known as GBCJ, LY2189265 was significantly superior to placebo in reducing key measures of glycemic control, including fasting serum glucose and hemoglobin A1C (HbA1C). In this study, LY2189265 showed an insulinotropic (stimulating the secretion of insulin) effect, suggesting it produced the desired outcome in participants. In Study GBCJ, LY2189265 was generally well-tolerated.

"We are excited about these data and the hope they could provide to the millions of diabetes patients who are struggling to maintain tight control of their blood glucose," said Pawel Fludzinski, Ph.D., global development leader for the GLP-1Fc team. "Evaluating the results of this study is an important step forward towards potentially bringing this innovative treatment to patients."

About Study GBCJ

In a 16-week, Phase II study of LY2189265, 262 patients with type 2 diabetes who were suboptimally controlled on at least two oral diabetes medicines were randomized to one of four arms: 1.0 mg of LY2189265 for 16 weeks; 0.5 mg of LY2189265 for four weeks followed by 1.0 mg for 12 weeks; and 1.0 mg of LY2189265 for four weeks followed by 2.0 mg for 12 weeks or placebo. The primary endpoint was glycemic control, as measured by change from baseline in HbA1C; additional endpoints evaluated included changes in fasting serum glucose, solid mixed meal glucose excursion and body weight.

For all do
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Advanced Medical ... development company engaged primarily in the development of ... therapeutic applications, today announced that a Life Sciences ... been awarded for which AMIC is the commercialization ... University (WSU) for the proposal titled "Optimized Injectable ...
(Date:12/19/2014)... 19, 2014 In today,s rapidly changing, ... communication tools are essential for survival. The world ... consumers, desires, preferences, and unmet needs are evolving ... groups across all industries are continually searching for ... the adoption of new market research techniques like ...
(Date:12/19/2014)... Dec. 18, 2014 Somewhere between dropping five ... was forgotten. But Audicus , a next-generation hearing ... this new year. Hearing loss is the ... population, though it is often unaddressed. Forty-eight million Americans ... a hearing aid, mainly due to price. Hearing aids ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2
... from analyses,looking at factors contributing to successful treatment ... Week,(DDW) this week. Both of these studies were ... from one study,offer new information on improvement of ... (mesalamine), which is from a class,of agents known ...
... 22, 2007 /PRNewswire/ -- A three-year,follow-up subset analysis ... 2007 showed that the CYPHER(R),Sirolimus-eluting Coronary Stent had ... bypass surgery) and better outcomes,than bare metal stents ... more coronary arteries. , The CYPHER(R) Stent results ...
Cached Medicine Technology:Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 2Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 3Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 4Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 5Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 2Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 3Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 4
(Date:12/22/2014)... Petersburg, FL (PRWEB) December 22, 2014 Christmas ... Sublime Beauty® has a fast and easy solution that will ... gift cards can be purchased from from $25 up to ... "We offer 100% customer satisfaction and a wide array of ... have no fees and no expiration dates. , Gift ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... 22, 2014 Recently, BambooFlooringChina.com, a famous ... woven bamboo flooring collection , and launched a bamboo ... promotion is valid until Jan. 30, 2015. , According ... is the hardest bamboo flooring available today; it has ... of traditional teak hardwoods. Strand woven bamboo is made ...
(Date:12/21/2014)... Gables, FL (PRWEB) December 21, 2014 When ... head lice, who do they call? The new answer is ... Blvd, Coral Gables FL 33134, their newest treatment center will ... this pest quickly, conveniently and without the use of harmful ... Opening is scheduled for January 1, 2015. Like the company’s ...
(Date:12/21/2014)... 2014 Recently, one of the best ... Prom Shop has introduced its new collection of ... big discounts on all its prom dresses & other ... insists on providing top quality dress products and great ... considered as one of the best prom dresses online ...
Breaking Medicine News(10 mins):Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2
... (AMS), which affects about half of those ascending to heights ... pulmonary or cerebral edema. ,The interest of the general ... past 25 years. This change is partly due to media ... In spite of these apparent changes, it is unknown whether ...
... deadly bird flu since it is still rampant in the region, ... ,"I think countries in this part of the world have ... it, the virus is still circulating," said Shigeru Omi, WHO's regional ... We remain concerned. We must avoid human transmission," he told reporters ...
... patients who have already gone blind in one eye ... and Therapeutics Bulletin (DTB). ,But that is ... (NICE), the body responsible for guiding the NHS on ... (Lucentis) and pegaptanib (Macugen) are licensed in the UK ...
... Biotechnology Co., Ltd. announced that a team led by ... completed a study to assess clinical efficacy, safety, ... for patients with peripheral vascular disease of the lower ... research and treatments for ataxia, cerebral palsy, spinal cord ...
... Those involved in biological weapons programs should be logically liable ... it seems to have happened in US and the Centers ... research laboratory at Texas A&M University to stop all work ... investigating reports of lab workers infected with the category B ...
... personnel involved in the Iraqi invasion of 2003 have ... published ahead of print in Occupational and Environmental Medicine. ... combat to pierce armoured vehicles, and spontaneously combusts on ... breathed in or eaten/drunk in contaminated food/water. ...
Cached Medicine News:Health News:Acute Mountain Sickness may Lead to Pulmonary or Cerebral Edema 2Health News:Bird Flu in Asia Still High Risk Says WHO Official 2Health News:Draft National Policy on Sight-saving Drugs unacceptable 2Health News:Adult Stem Cells Show Promise for Peripheral Vascular Disease 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 3Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 4
McDavid® Patella Knee Support helps relieve the symptoms of chondromalacia patellar subluxation and patellar tendonitis. Features two medial and two lateral spring-steel stays. 3/16" thick neopre...
... Exotec® Dual Instabilities Lite Lightweight mechanical ... patients with ACL, MCL or LCL ... tibia movement and reduce load on ... or add-ons. Supports the injured or ...
... Orthosis Custom-fitted static-progressive orthosis ... Goniometer version has calibrated ... metal contacts skin. Includes ... bag. One size fits ...
... Polyamide Hinge Wraparound design can ... fit. Multilock polyamide hinge prevents ... extension can be set for ... level. Provides medial/lateral support during ...
Medicine Products: